In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

To QB or not to QB? That was the question Eli Stowers asked himself as the 2023 college football season approached for New Mexico State. The question answered itself. The answer not to QB.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Eli Lilly (LLY) closed at $795.67 in the latest trading session, marking a -0.08% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.1%. Elsewhere ...

Shelby Knowles / Bloomberg via Getty Images Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive ...

Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit ...

Eli Puretz wants others to avoid the mistake he made. Puretz, a 29-year old real estate investor, is facing a sentence of five years in prison for his role in a multi-million-dollar commercial ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...

The bottom line: We're maintaining our $580 fair value estimate for Eli Lilly, and the firm's tirzepatide molecule (diabetes drug Mounjaro and obesity/sleep apnea drug Zepbound) and ...

Newly-released data from the Center for Immigration Studies is sounding the alarm on the declining US labor force, by showing fewer native-born Americans are joining the workforce — with men ...